Wegovy is stronger than Ozempic in terms of dose. Both medications contain the exact same drug, semaglutide, but Wegovy tops out at 2.4 mg per week while Ozempic maxes out at 2.0 mg. That higher ceiling translates to more weight loss, though the two products are designed for different purposes and aren’t interchangeable.
Same Drug, Different Doses
Semaglutide is the active ingredient in both Wegovy and Ozempic. It mimics a gut hormone called GLP-1 that slows digestion, reduces appetite, and helps regulate blood sugar. The molecule is identical in both pens. What differs is how much you inject each week and what condition it’s prescribed for.
Ozempic is FDA-approved for type 2 diabetes, with maintenance doses of 0.5 mg, 1.0 mg, or 2.0 mg once weekly. Wegovy is approved for weight management (in adults and children 12 and older), for a liver condition called MASH, and for reducing cardiovascular risk in adults with obesity or overweight who have heart disease. Its maintenance dose is 2.4 mg once weekly. So when people say Wegovy is “stronger,” they’re really pointing to that extra 0.4 mg at the top end, plus the fact that most Wegovy patients are titrated all the way up to 2.4 mg, while many Ozempic patients stabilize at 1.0 mg.
How Much More Weight Loss Does the Higher Dose Produce?
The weight loss gap between the two doses is meaningful. In the STEP 10 clinical trial, participants taking 2.4 mg of semaglutide weekly (the Wegovy dose) lost an average of 13.9% of their body weight over one year, compared to 2.7% with a placebo. For someone starting at 220 pounds, that’s roughly 30 pounds.
Ozempic’s lower doses produce weight loss too, but less of it. Clinical trials for the 1.0 mg dose typically show losses in the range of 5% to 7% of body weight. The 2.0 mg Ozempic dose narrows the gap somewhat, but it still falls short of the 2.4 mg results. The relationship is straightforward: more semaglutide means more appetite suppression and more weight loss, up to the doses that have been studied.
Blood Sugar Control at Different Doses
For people with type 2 diabetes, the comparison looks a little different. In the SUSTAIN FORTE trial, participants on semaglutide 2.0 mg (Ozempic’s highest dose) lowered their A1c by 2.2 percentage points over 40 weeks, while those on 1.0 mg dropped 1.9 percentage points. Both are substantial reductions. The 2.4 mg Wegovy dose wasn’t specifically tested for diabetes management in those trials because Wegovy isn’t approved for that purpose.
If your primary concern is blood sugar, Ozempic at 1.0 or 2.0 mg already delivers strong A1c improvements, and a doctor is unlikely to prescribe Wegovy for diabetes alone. The “stronger” dose matters most when weight loss or cardiovascular protection is the goal.
Side Effects Scale With the Dose
Gastrointestinal side effects from semaglutide are dose-dependent. The higher you go, the more likely you are to experience nausea, vomiting, or diarrhea, particularly during the weeks when your dose is being increased. At the 2.4 mg level, the median duration of nausea in clinical trials was about 8 days, with diarrhea lasting around 3 days and vomiting about 2 days.
These side effects tend to decline over time as your body adjusts. Both medications use a gradual titration schedule, starting at a low dose and stepping up every four weeks, specifically to minimize GI discomfort. Wegovy’s schedule takes about 16 to 20 weeks to reach the full 2.4 mg maintenance dose. But because that final dose is higher, some people find the last step up (from 1.7 mg to 2.4 mg) noticeably rougher than anything they experienced on Ozempic’s schedule.
Heart Protection
One area where Wegovy’s higher dose has proven its value is cardiovascular risk. The SELECT trial found that semaglutide at 2.4 mg weekly reduced the risk of major cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% compared to placebo in people with established heart disease who had obesity or overweight but did not have diabetes. This led the FDA to approve Wegovy specifically for cardiovascular risk reduction, a distinction Ozempic does not carry for patients without diabetes.
Ozempic has its own cardiovascular and kidney benefits, but those approvals are limited to adults with type 2 diabetes. If you don’t have diabetes but do have heart disease and excess weight, Wegovy is the version with the evidence and the FDA indication behind it.
Switching From Ozempic to Wegovy
Because it’s the same molecule, switching between the two is relatively simple. U.S. Department of Veterans Affairs guidance, which mirrors standard clinical practice, outlines the process: if you’re already on Ozempic 1.0 mg, you can start Wegovy at 1.0 mg, step up to 1.7 mg for four weeks, then move to the 2.4 mg maintenance dose. If you’re already on Ozempic 2.0 mg and have been there for at least four weeks, you can go directly to Wegovy 2.4 mg. The first Wegovy injection is given seven days after the last Ozempic injection.
The most common reason for this switch is wanting more weight loss than Ozempic’s top dose can deliver, or qualifying for Wegovy’s cardiovascular indication.
Cost Differences
Pricing for the two medications has shifted recently. As of early 2025, the Wegovy injectable pen costs about $349 per month, with a discounted $199 price for new patients during the first two months. The Ozempic injectable pen runs between $349 and $499 per month depending on dose, with the same $199 introductory offer. Wegovy pills sold through direct-to-consumer channels range from $149 to $299 monthly depending on dosage.
Insurance coverage is often the bigger factor. Many insurance plans cover Ozempic for type 2 diabetes but restrict or deny Wegovy for weight management. This is a major reason some people end up on Ozempic for weight loss even though Wegovy would technically be the better-matched product. If your plan does cover both, Wegovy at its full 2.4 mg dose will generally produce better weight loss results than Ozempic at any of its approved doses.